Janux Therapeutics (JANX) announced that the first participant has been dosed in a Phase 1 clinical study of JANX011, a CD19-targeted bispecific engineered using the company’s proprietary Adaptive Immune Response Modulator platform. JANX011 is being developed for autoimmune diseases and is designed to enable deep and durable immune reset through targeted depletion of CD19-expressing B cells in blood and tissue.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JANX:
- Janux Therapeutics CMO Zachariah McIver to depart, William Go to succeed
- Janux Therapeutics Inks Global Oncology Collaboration With BMS
- Janux Therapeutics: Bristol Myers Collaboration Validates Tumor-Activated Platform and Enhances Risk–Reward Profile
- Janux Therapeutics enters exclusive license agreement with Bristol Myers
- Janux Therapeutics downgraded to Hold from Buy at Clear Street